Gapping up
In reaction to strong earnings/guidance:
- DAL +2.4%, ZUMZ -0.7% (Zumiez reports Sept comps of +1.2% vs +9.3% year ago and +9.5% last month)
Other news:
- CGEN +20.3% (Compugen & Bristol-Myers Squibb (BMY) enter clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701 in combination with Opdivo in patients with advanced solid tumors)
- CRSP +14.6% (CRISPR Therapeutics and Vertex announce FDA has lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease)
- TUP +8.8% (CFO Michael S. Poteshman announces upcoming retirement)
- NTLA +7.6% (following CRSP / VRTX news)
- EDIT +6.6% (following CRSP / VRTX news)
- ACRX +6.5% (continued strength after 35% move higher on Wed)
- KTWO +4.2% (announces receipt of FDA clearance including surgical guidance that enhances MESA platform using patient-specific rods and rails)
- TAHO +3.8% (Guatemalan Constitutional Court finalized resolution)
- GPRE +3% (to sell three ethanol plants)
- ABX +2.3% (preannounces Q3 sales and production; reaffirms FY18 production)
- EMKR +2% (Northern Right Capital increases holding/turns active with 5.5% stake)
- RIGL +1.6% (announces that the European Medicines Agency has validated the Marketing Authorization Application for fostamatinib in adult chronic immune thrombocytopenia)
Analyst comments:
- LITE +0.8% (upgraded to Overweight from Neutral at JP Morgan)
![]()